WHO perspective on preventing avoidable harm from medicines
| Autor: | Shanthi N. Pal, Mary Couper, Jacqueline Sawyer, Lembit Rägo |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
Economic growth Factor cost business.industry Perspective (graphical) General Engineering Alternative medicine Developing country General Medicine Pharmacology World health Cripple Harm Pharmacovigilance medicine General Earth and Planetary Sciences Letters business General Environmental Science |
| Zdroj: | BMJ. 332:1393.3-1394 |
| ISSN: | 1468-5833 0959-8138 |
| DOI: | 10.1136/bmj.332.7554.1393-b |
| Popis: | EDITOR—The BMJ news item on adverse drug reactions is important.1 The estimated annual expenditure of $870m towards issues related to such effects would be hard on any economy; such figures could seriously cripple countries with lesser resources. The cost factor should then be at least one of the reasons for all developing countries to promote pharmacovigilance. Started in 1968, the World Health … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|